Antimicrobial Resistance Rates and Surveillance in Sub-Saharan Africa: Where Are We Now?
Open accessThe DOI matches its Crossref record; 190 of the 190 references it cites were found in a registry or an index; 74 of the 94 sources its claims cite were checked for support.
Abstract
Introduction: Although antimicrobials have traditionally been used to treat infections and improve health outcomes, resistance to commonly used antimicrobials has posed a major challenge. An estimated 700,000 deaths occur globally every year as a result of infections caused by antimicrobial-resistant pathogens. Antimicrobial resistance (AMR) also contributes directly to the decline in the global economy. In 2019, sub-Saharan Africa (SSA) had the highest mortality rate (23.5 deaths per 100,000) attributable to AMR compared to other regions. Methods: We searched PubMed for articles relevant to AMR in pathogens in the WHO-GLASS list and in other infections of local importance in SSA. In this review, we focused on AMR rates and surveillance of AMR for these priority pathogens and some of the most encountered pathogens of public health significance. In addition, we reviewed the implementation of national action plans to mitigate against AMR in countries in SSA. Results and Discussion: The SSA region is disproportionately affected by AMR, in part owing to the prevailing high levels of poverty, which result in a high burden of infectious diseases, poor regulation of antimicrobial use, and a lack of alternatives to ineffective antimicrobials. The global action plan as a strategy for prevention and combating AMR has been adopted by most countries, but fewer countries are able to fully implement country-specific action plans, and several challenges exist in many settings. Conclusion: A concerted One Health approach will be required to ramp up implementation of action plans in the region. In addition to AMR surveillance, effective implementation of infection prevention and control, water, sanitation, and hygiene, and antimicrobial stewardship programs will be key cost-effective strategies in helping to tackle AMR.
Overview
CoChat Summary
TL;DR
This review summarizes antimicrobial resistance rates among WHO-GLASS and locally important pathogens in sub-Saharan Africa and assesses national action plan implementation. It reports that SSA has the highest AMR-attributable mortality and that NAP implementation remains limited by funding, surveillance, and multisectoral coordination gaps.
Key findings
- In 2019, SSA had the highest AMR-attributable mortality rate (23.5 deaths per 100,000), with Western SSA highest at 27.3 deaths per 100,000; globally, 4.95 million deaths were associated with AMR and 1.27 million were attributable to AMR.
- Resistance was widespread among reviewed pathogens: diarrheagenic E. coli prevalence ranged from 14.7% to 82%; multidrug-resistant S. Typhi subclade 4.3.1 prevalence ranged from 60.4% to 97%; MRSA prevalence ranged from 1.25% to 53.4%; carbapenem-resistant P. aeruginosa prevalence ranged from 6% to 34.8%; and East Africa had the highest A. baumannii carbapenem resistance prevalence at 23%.
- NAP implementation was limited: 11 (25%) of 44 SSA countries had NAPs on AMR; 32% performed routine AMR surveillance on clinical pathogens and 2% on veterinary pathogens; 59% had a dedicated National Reference Laboratory; by February 2022, 15 SSA countries had fully developed NAPs. Thematic performance was 38±12% for awareness creation and training, 18±13% for surveillance, 33±13% for infection prevention and control, 28±23% for optimal antimicrobial use, and 59±12% for multisector and One Health collaboration.
- Burden estimates included 141,918 cholera infections per year in SSA; approximately 1.5 million typhoid cases and 19,900 deaths annually in SSA, accounting for about 17% of global typhoid deaths; 421,600 invasive non-typhoidal Salmonella cases and 66,520 deaths in SSA; and 31% of neonatal sepsis mortalities (690,000) plausibly attributed to antimicrobial-resistant infections.
Methods
- Narrative review of English original articles and reviews retrieved from PubMed and Google Scholar, covering the WHO-Africa region divided into Western, Eastern, Central, and Southern SSA; search terms included antimicrobial resistance, multi-drug resistance, sub-Saharan Africa, surveillance, global action plan, national action plan, and One Health approach; articles published between 2000 and 2022 were considered.
- Pathogens were selected as WHO-GLASS priority pathogens plus Vibrio cholerae; inclusion criteria covered articles on selected pathogens from SSA countries, articles reporting antibiotic resistance rates and genes, and both monomicrobial and polymicrobial studies; exclusions were non-WHO-GLASS pathogens, articles from beyond SSA, conference abstracts, intervention trials, and duplicates.
- The review presents resistance rates from cited studies in tables and discusses NAP implementation; it does not report a pooled meta-analysis.
Limitations
- The paper states that precise burden estimates for resistant K. pneumoniae in SSA are lacking and that available data are generated in referral/research/university hospitals, which do not represent the broad range of healthcare settings; it also states that few A. baumannii reports come from low-income countries, making prevalence estimates difficult.
- The paper states that the paucity of data in SSA on AMR prevalence and antimicrobial use is a major impediment, and it lists NAP implementation challenges including inadequate funding, poor coordination, inadequate surveillance data, poor infrastructure and health systems, staffing shortages, and lack of monitoring and quality assurance systems.
- Evident from the text: as a narrative review using PubMed/Google Scholar and heterogeneous published studies, resistance rates are not pooled or systematically appraised, and many estimates come from single-center or referral-hospital studies that may not be generalizable.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
50 Valid · 5 Not valid · 14 Not checked · 32 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In 2019, sub-Saharan Africa (SSA) had the highest mortality rate (23.5 deaths per 100,000) attributable to AMR compared to other regions.”
- Also stated in: § Impact of Antimicrobial Resistance · plain
“Compared to other Global Burden of Disease study regions, sub-Saharan Africa (SSA) and South Asia had the highest mortalities (23.5 deaths per 100,000 and 21.5 deaths per 100,000, respectively) attributable to AMR.”
§ Antimicrobial Resistance Rates and Surveillance in Sub-Saharan Africa: Where Are We Now? > Abstract
What the sources say
- Partly supportedcites [8] Murray CJ, Ikuta KS, Sharara F, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399:629-655. doi:10.1016/S0140-6736(21)02724-0 sourceExperimental — accuracy not yet measured
The Results report that sub-Saharan Africa had the highest all-age death rate attributable to AMR in 2019. However, they give 27.3 deaths per 100,000 for western sub-Saharan Africa, the highest of the 21 regions; our copy does not substantiate the claimed 23.5 deaths per 100,000 for sub-Saharan Africa as a whole. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Impact of Antimicrobial Resistance · plain
Every source the paper cites for this claim was checked and supports it.
In the paper
“Indeed, the rapid emergence of antimicrobial-resistant pathogens is often accelerated by the inappropriate use and overuse of antimicrobial agents, especially antibiotics, in humans, animals, and agriculture/the environment.”
§ Antimicrobial Resistance Rates and Surveillance in Sub-Saharan Africa: Where Are We Now? > Role of Antimicrobial Use in Increasing Rates of AMR
What the sources say
- Supportedcites [18] Sartelli M, Catena F, Catena F, et al. Antibiotic use in low and middle-income countries and the challenges of antimicrobial resistance in surgery. Antibiotics. 2020;9(8):497. doi:10.3390/antibiotics9080497 source
Section 2, “Antimicrobial Resistance: A Global Challenge,” says antibiotic use, misuse and abuse in human, animal and environmental sectors drive AMR, and that misuse selects resistant microorganisms. Section 3, “Antimicrobial Resistance in LMICs,” also identifies antibiotic use in agriculture as a challenge. (LLM, conf=0.94)
- Supportedcites [19] Van TTH, Yidana Z, Smooker PM, et al. Antibiotic use in food animals worldwide, with a focus on Africa: pluses and minuses. J Glob Antimicrob Resist. 2020;20:170-177. doi:10.1016/j.jgar.2019.07.031 source
The Introduction identifies repeated antibiotic use in food animals as a significant contributor to antimicrobial resistance and acknowledges the contribution of misuse in humans. Section 4 says widespread antibiotic use in animals accelerates the emergence of resistance and describes the environment as a reservoir and route of spread, including antibiotic use in aquaculture. (LLM, conf=0.90)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In neonatal sepsis, 31% of mortalities (690,000) reported were plausibly attributed to antimicrobial-resistant infections.”
§ Antimicrobial Resistance Rates and Surveillance in Sub-Saharan Africa: Where Are We Now? > Impact of Antimicrobial Resistance
What the sources say
- Supportedcites [11] Li G, Bielicki JA, Ahmed ANU, et al. Towards understanding global patterns of antimicrobial use and resistance in neonatal sepsis: insights from the NeoAMR network. Arch Dis Child. 2020;105(1):26-31. doi:10.1136/archdischild-2019-316816 source
The Introduction reports a previous estimate that 214,000 of 690,000 annual neonatal deaths associated with sepsis (31%) were potentially attributable to antimicrobial resistance. The paper presents this as an estimate from Laxminarayan et al., not a finding of the NeoAMR study. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The study found that the consumption rate increased from 9.8 (9.2-10.5)daily defined doses (DDD) to 14.3 (13.2-15.6)DDD per 1000 population per day.”
§ Antimicrobial Resistance Rates and Surveillance in Sub-Saharan Africa: Where Are We Now? > Role of Antimicrobial Use in Increasing Rates of AMR
What the sources say
- Supportedcites [26] Browne AJ, Chipeta MG, Haines-Woodhouse G, et al. Global antibiotic consumption and usage in humans, 2000-18: a spatial modelling study. Lancet Planetary Health. 2021;5(12):e893-e904. doi:10.1016/S2542-5196(21)00280-1 source
The Results report that global antibiotic consumption rose from 9.8 (95% uncertainty interval 9.2–10.5) to 14.3 (13.2–15.6) defined daily doses per 1000 people per day between 2000 and 2018. These are the figures and period attributed to the study. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A study published in 2021 reported that there was a 46% increase in the global consumption of antimicrobials between 2000 and 2018.”
§ Antimicrobial Resistance Rates and Surveillance in Sub-Saharan Africa: Where Are We Now? > Role of Antimicrobial Use in Increasing Rates of AMR
What the sources say
- Partly supportedcites [26] Browne AJ, Chipeta MG, Haines-Woodhouse G, et al. Global antibiotic consumption and usage in humans, 2000-18: a spatial modelling study. Lancet Planetary Health. 2021;5(12):e893-e904. doi:10.1016/S2542-5196(21)00280-1 sourceExperimental — accuracy not yet measured
The Introduction (Added value of this study) reports a 46% increase in global antibiotic consumption since 2000, and the Results give the 2000 and 2018 consumption rates. The study measures antibiotics, not antimicrobials as a whole, so the claim broadens its scope. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
38 more claims · 18 with their cited sources checked
Create a free account to see all 101 claims and to verify the 4 references still open.
- Probably not a substantial claim. 27
- It may state two separate claims as one. 42
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Such sparsity is mainly due to insufficient laboratory infrastructure and capacity, scarce or absent microbiological facilities, weak health systems and governance and information systems, and scarce resources.60, 72, 73”
From Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050 (2024) · cites this paper as [73]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Antimicrobial Resistance Rates and Surveillance in Sub-Saharan Africa: Where Are We Now? > Carbapenem-Resistant Acinetobacter baumannii
“Out of the 29 countries, only 16 countries reported the detection of A. baumannii within their territories at least once in the last 21 years.”
§ Antimicrobial Resistance Rates and Surveillance in Sub-Saharan Africa: Where Are We Now? > Carbapenem-Resistant Acinetobacter baumannii
“Accordingly, 11 out of the 29 have no A. baumannii reports at all in the three searched databases.”
Citations
Cites
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
Murray, C. J. L., Ikuta, K. S., Sharara, F., Swetschinski, L., Robles Aguilar, G., Gray, A., Han, C., Bisignano, C., Rao, P., Wool, E., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02724-0 · Cited by 16,316 · cited 2×
“aeruginosa accounting for 38,100 deaths globally.(151) The prevalence of carbapenem-resistant P.”
BackgroundTacconelli, E., Carrara, E., Savoldi, A., Harbarth, S., Mendelson, M., Monnet, D. L., Pulcini, C., Kahlmeter, G., Kluytmans, J., Carmeli, Y., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30753-3 · Cited by 6,142 · cited 2×
“aeruginosa as one of the three critical global priority pathogens that require development of new antibiotics.(144) It is estimated that in 2019, antimicrobialresistant P.”
BackgroundAcinetobacter baumannii : Emergence of a Successful Pathogen
Peleg, A. Y., Seifert, H., & Paterson, D. L. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00058-07 · Cited by 3,316 · cited 1×
“Acinetobacter baumannii is often implicated in bloodstream, urinary tract, pneumonia, skin and soft tissue infections, and meningitis.(138,139) Owing to its AMR,(140) A.”
BackgroundAntibiotic resistance in the environment
Larsson, D. G. J., & Flach, C.-F. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00649-x · Cited by 3,164
Cassini, A., Högberg, L. D., Plachouras, D., Quattrocchi, A., Hoxha, A., Simonsen, G. S., Colomb-Cotinat, M., Kretzschmar, M. E., Devleesschauwer, B., Cecchini, M., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30605-4 · Cited by 2,945 · cited 1×
“conducted in the European Union, published in 2019, estimates an annual number of disability-adjusted life-years (DALYs) at 148,727 (131,757–166,361) per 1,000,000 population, infections at 112,782 (103,186–122,006), and attributable deaths at 6810 (6096–7559).(156) While surveillance systems are in place in developed…”
BackgroundAntimicrobial Resistance: Implications and Costs
Dadgostar, P. (2019) · Infection and Drug Resistance · doi:10.2147/idr.s234610 · Cited by 2,024 · cited 1×
“Infections caused by antimicrobial-resistant pathogens are reported to result in approximately 700,000 deaths globally every year.(3)”
BackgroundManyi-Loh, C., Mamphweli, S., Meyer, E., & Okoh, A. (2018) · Molecules · doi:10.3390/molecules23040795 · Cited by 1,808 · cited 19×
“Some of the challenges that hinder the implementation of NAPs are: 1) a lack of political commitment, 2) inadequate funding, 3) poor coordination and collaboration between the different sectors, 4) inadequate surveillance Infection and Drug Resistance 2022:15 https://doi.org/10.2147/IDR.S342753 DovePress 3601 Powered…”
BackgroundInfluentialTroeger, C., Blacker, B. F., Khalil, I. A., Rao, P. C., Cao, S., Zimsen, S. R., Albertson, S. B., Stanaway, J. D., Deshpande, A., Abebe, Z., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30362-1 · Cited by 1,476 · cited 1×
“According to the 2016 Global Burden of Disease (GBD) report, cumulatively these two pathotypes result in 63,523 deaths among all ages annually, throughout the world.(36) Other important E.”
BackgroundThe threat of antimicrobial resistance in developing countries: causes and control strategies
Ayukekbong, J. A., Ntemgwa, M., & Atabe, A. N. (2017) · Antimicrobial Resistance & Infection Control · doi:10.1186/s13756-017-0208-x · Cited by 1,315 · cited 17×
“Some of the challenges that hinder the implementation of NAPs are: 1) a lack of political commitment, 2) inadequate funding, 3) poor coordination and collaboration between the different sectors, 4) inadequate surveillance Infection and Drug Resistance 2022:15 https://doi.org/10.2147/IDR.S342753 DovePress 3601 Powered…”
BackgroundInfluentialHealth systems financing and the path to universal coverage
Evans, D. B., & Etienne, C. (2010) · Bulletin of the World Health Organization · doi:10.2471/blt.10.078741 · Cited by 1,279
Research works printed but not linked: 3
- Taylor J, Hafner M, Yerushalmi E, et al. Estimating the Economic Costs of Antimicrobial Resistance. Cambridge, UK: Model and Results (RAND Corporation); 2014. Infection and Drug Resistance 2022:15 https://doi.org/10.2147/IDR.S342753 DovePress
- 2022, StatPearls
- Murray, 2022, Lancet, 399, 629, 10.1016/S0140-6736(21)02724-0 · DOI · Paper page
Cited by
Naghavi, M., Vollset, S. E., Ikuta, K. S., Swetschinski, L. R., Gray, A. P., Wool, E. E., Robles Aguilar, G., Mestrovic, T., Smith, G., Han, C., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01867-1 · Cited by 3,791
“60,72,73 In some countries, available data are fragmented, undersampled, or not representative of the broader population.”
Sartorius, B., Gray, A. P., Davis Weaver, N., Robles Aguilar, G., Swetschinski, L. R., Ikuta, K. S., Mestrovic, T., Chung, E., Wool, E. E., Han, C., et al. (2024) · The Lancet Global Health · doi:10.1016/s2214-109x(23)00539-9 · Cited by 354
“35,36 Available data in some countries are often fragmented, undersampled, or not necessarily representative of the general underlying population.”
BackgroundGlobal burden of antimicrobial resistance and forecasts to 2050
Kariuki, S. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01885-3 · Cited by 190
Self-citationGlobal Strategies to Combat Antimicrobial Resistance: A One Health Perspective
Mudenda, S., Chabalenge, B., Daka, V., Mfune, R. L., Salachi, K. I., Mohamed, S., Mufwambi, W., Kasanga, M., & Matafwali, S. K. (2023) · Pharmacology & Pharmacy · doi:10.4236/pp.2023.148020 · Cited by 144
Sono, T. M., Yeika, E., Cook, A., Kalungia, A., Opanga, S. A., Acolatse, J. E. E., Sefah, I. A., Jelić, A. G., Campbell, S., Lorenzetti, G., et al. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2259106 · Cited by 95
“For instance in Ghana, there are still concerns due to the lack of available resources and commitment to fully progress their NAP [27], which is similar to other African countries with limited resources and technologies allocated to AMR mitigation [28].”
BackgroundAntibiotic Use in Livestock Farming: A Driver of Multidrug Resistance?
Matheou, A., Abousetta, A., Pascoe, A. P., Papakostopoulos, D., Charalambous, L., Panagi, S., Panagiotou, S., Yiallouris, A., Filippou, C., & Johnson, E. O. (2025) · Microorganisms · doi:10.3390/microorganisms13040779 · Cited by 102
“Moreover, recent surveillance data underscore global dissemination of MDR K. pneumoniae , notably in cattle farms across Africa and Asia [28,29]; MDR CoNS widely prevalent in European pig and dairy farms [30]; and A. baumannii found in raw milk in African countries [31].”
Antimicrobial Resistance in Sub-Saharan Africa: A Comprehensive Landscape Review
Totaro, V., Guido, G., Cotugno, S., Vita, E. D., Asaduzzaman, M., Patti, G., Segala, F. V., Putoto, G., Frallonardo, L., Farkas, F. B., et al. (2025) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.25-0035 · Cited by 87
“140,141 Africa has the highest global mortality rate from AMR infections.”
Moyo, P. N., Moyo, E., Mangoya, D., Mhango, M., Mashe, T., Imran, M., & Dzinamarira, T. (2023) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2023.02.020 · Cited by 77
Gashaw, T., Yadeta, T. A., Weldegebreal, F., Regassa, L. D., Jambo, A., & Assefa, N. (2025) · Systematic Reviews · doi:10.1186/s13643-025-02783-6 · Cited by 102
“If no intervention strategies are initiated, it is estimated that by 2050, mortalities attributed to AMR will increase to 10 million annually, with Africa and Asia accounting for the highest burden of deaths [99].”
Antimicrobial resistance: Linking molecular mechanisms to public health impact
Muteeb, G., Kazi, R. N. A., Aatif, M., Azhar, A., Oirdi, M. E., & Farhan, M. (2025) · SLAS DISCOVERY · doi:10.1016/j.slasd.2025.100232 · Cited by 74
Antibiotic Use in Livestock and Environmental Antibiotic Resistance: A Narrative Review
Abate, T. A., & Birhanu, A. G. (2025) · Environmental Health Insights · doi:10.1177/11786302251357775 · Cited by 74
“76,77 Furthermore, the economic burden of AMR is substantial, impacting both human and animal healthcare systems.”
Immunomodulation, Bioavailability and Safety of Bacteriocins
Guryanova, S. V. (2023) · Life · doi:10.3390/life13071521 · Cited by 55
Barathan, M., Ng, S. L., Lokanathan, Y., Ng, M. H., & Law, J. X. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063080 · Cited by 50
Matee, M. I., Mshana, S. E., Majigo, M. V., Komba, E. V. G., Moremi, N., Lutamwa, J., Kapona, O., Sekamatte, M., & Mboera, L. E. G. (2023) · Bulletin of the National Research Centre/Bulletin of the National Research Center · doi:10.1186/s42269-023-00986-2 · Cited by 53
“2021), and there is lack of alternatives to ineffective antimicrobials (Kariuki et al 2022).”
BackgroundAntimicrobial Resistance in the WHO African Region: A Systematic Literature Review 2016–2020
Gahimbare, L., Muvunyi, C. M., Guessennd, N., Rutanga, J. P., Gashema, P., Fuller, W. L., Mwamelo, A. J., Coulibaly, S. O., Mosha, F. S., Perovic, O., et al. (2024) · Antibiotics · doi:10.3390/antibiotics13070659 · Cited by 45
“Therefore, the timely and continuous surveillance of bacterial infections, as well as the reporting and sharing of AMR data, are needed in Africa to guide the required new approaches for control and the treatment of bacterial infections [3,7,20,21].”
BackgroundSohaili, A., Asin, J., & Thomas, P. P. M. (2024) · Antibiotics · doi:10.3390/antibiotics13030197 · Cited by 42
“Concurrently, a recurring theme in AMR interventions is the substantial dependence on external funding from institutions such as the Fleming Fund, WHO, and USAID, which are pivotal in bolstering AMS initiatives via training, material support, and laboratory equipment procurement [13,26].”
BackgroundBabirye, S. R., Nsubuga, M., Mboowa, G., Batte, C., Galiwango, R. M., & Kateete, D. P. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-10282-7 · Cited by 37
“AMR is associated with a negative effect on the economies of communities and countries most especially low-income and middle-income countries (LMICs) having a higher burden of infectious diseases [3].”
Mudenda, S., Chilimboyi, R., Matafwali, S. K., Daka, V., Mfune, R. L., Kemgne, L. A. M., Bumbangi, F. N., Hangoma, J. M., Chabalenge, B., Mweetwa, L. L., et al. (2023) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlae023 · Cited by 37
Majalija, S., Wabwire, T. F., Tumwine, G., & Waiswa, P. (2023) · Veterinary Medicine International · doi:10.1155/2023/6644271 · Cited by 36
Valavarasu, S., Sangu, Y., & Mahapatra, T. (2025) · Scientific Reports · doi:10.1038/s41598-025-14078-w · Cited by 33
Rware, H., Kansiime, M. K., Mugambi, I., Makale, F., Ikiror, D., Buke, W., Danielsen, S., Karanja, D., Duncan, C., Byskov, M. F., et al. (2024) · CABI Agriculture and Bioscience · doi:10.1186/s43170-024-00223-4 · Cited by 29
“Kariuki et al. (2022) and WHO (2022) point out that Kenya, driven by its national action plan on AMR, has made considerable progress over the last years to build public awareness and knowledge on AMR and risky antibiotics use.”
BackgroundFinancial and economic costs of healthcare-associated infections in Africa
Hutton, G., Chase, C., Kennedy-Walker, R., & Hamilton, H. (2024) · Journal of Hospital Infection · doi:10.1016/j.jhin.2024.04.015 · Cited by 34
Kapatsa, T., Lubanga, A. F., Bwanali, A. N., Harawa, G., Mudenda, S., Chipewa, P., Kamayani, M., Makole, T., Ali, A., Mohamed, A. M., et al. (2025) · Infection and Drug Resistance · doi:10.2147/idr.s503730 · Cited by 30
Extended-spectrum β-lactamase-producing Escherichia coli from poultry: A review
Widodo, A., Khairullah, A. R., Effendi, M. H., Moses, I. B., & Agustin, A. L. D. (2024) · Veterinary World · doi:10.14202/vetworld.2024.2017-2027 · Cited by 24
The nature of self-medication in Uganda: a systematic review and meta-analysis
Makeri, D., Dilli, P. P., Pius, T., Tijani, N. A., Opeyemi, A. A., Lawan, K. A., Jakheng, S. P. E., Muhwezi, R., Shabohurira, A., Usman, I. M., et al. (2025) · BMC Public Health · doi:10.1186/s12889-025-21380-9 · Cited by 30
“The prevalent use of antibiotics and antimalarials partly explains the 38,000 AMR-attributable deaths in the country in 2019 [67].”
A Review of the Important Weapons against Antimicrobial Resistance in Sub-Saharan Africa
Gahamanyi, N., Umuhoza, T., Saeed, S. I., Mayigane, L. N., & Hakizimana, J. N. (2023) · Applied Biosciences · doi:10.3390/applbiosci2020011 · Cited by 25
Ripanda, A., Rwiza, M. J., Nyanza, E. C., Hossein, M., Said, A., Mahmoud, A. E. D., Murthy, H. C. A., Bakari, R., Vuai, S. A. H., & Machunda, R. L. (2025) · Emerging contaminants · doi:10.1016/j.emcon.2025.100475 · Cited by 25
Okeke, E. S., Nwankwo, C. E. I., Ezeorba, T. P. C., Ogugofor, M. O., & Nwuche, C. O. (2024) · Journal of Water Process Engineering · doi:10.1016/j.jwpe.2024.106636 · Cited by 25
Kamara, I. F., Kanu, J. S., Maruta, A., Fofanah, B. D., Kamara, K. N., Sheriff, B., Katawera, V., D’Almeida, S. A., Musoke, R., Nuwagira, I. B., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-078367 · Cited by 22
Yakobi, S. H., Zuma, L. K., & Pooe, O. J. (2024) · ChemistrySelect · doi:10.1002/slct.202303341 · Cited by 24
Lubanga, A. F., Bwanali, A. N., Kambiri, F., Harawa, G., Mudenda, S., Mpinganjira, S., Singano, N., Makole, T., Kapatsa, T., Kamayani, M., et al. (2024) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2024.2362270 · Cited by 26
“[3,23].”
BackgroundHu, X., Gan, H.-Q., Gui, W.-Z., Yan, K., Sessler, J. L., Yi, D., Tian, H., & He, X. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2408716121 · Cited by 19
“It is estimated that 700,000 deaths worldwide are associated with bacterial antimicrobial resistance every year ( 4 ).”
Mudenda, S., Mufwambi, W., & Mohamed, S. (2024) · Pharmacology & Pharmacy · doi:10.4236/pp.2024.1512024 · Cited by 20
Abejew, A. A., Wubetu, G. Y., & Fenta, T. G. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e32663 · Cited by 20
“In most sub-Saharan African countries, AMR has not been a priority, even for those whose customized national AMR action plans (NAP) are developed based on global AMR action plans (GAP), the implementation is still inadequate [29,30,42], despite the high burden of AMR [17,31].”
BackgroundLimwado, G. D., Aron, M. B., Mpinga, K., Phiri, H., Chibvunde, S., Banda, C., Ndarama, E. P. L., Walyaro, C., & Connolly, E. (2024) · IJID Regions · doi:10.1016/j.ijregi.2024.100444 · Cited by 26
“Sub-Saharan Africa faces a more severe situation con-∗ cerning antimicrobial resistance (AMR), as estimated in 2019, with the region recording the highest mortality rate (23.5 deaths per 100,000) attributed to AMR compared with other regions [ 7 ].”
BackgroundInfluentialBoltena, M. T., Wolde, M., Hailu, B., El‐Khatib, Z., Steck, V., Woldegerima, S., Siraneh, Y., & Sudhakar, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-62651-6 · Cited by 19
Mapping socioeconomic factors driving antimicrobial resistance in humans: An umbrella review
Ljungqvist, G. V., van Kessel, R., Mossialos, E. A., Saint, V., Schmidt, J., Mafi, A., Shutt, A., Chatterjee, A., Charani, E., & Anderson, M. (2025) · One Health · doi:10.1016/j.onehlt.2025.100986 · Cited by 19
“This was found with resistance rates [22,43] with the notable exception of MRSA infections.”
Mackline, H., Kiggundu, R., Tabajjwa, D., Tumwine, C., Lwigale, F., Mwanja, H., Waswa, J. P., Mayito, J., Bulwadda, D., Byonanebye, D. M., et al. (2024) · Wellcome Open Research · doi:10.12688/wellcomeopenres.23133.1 · Cited by 18
“In low-and middle-income countries (LMICs), the capability for AMR surveillance varies 9 , with Sub-Saharan Africa (SSA) and Southeast Asia having the least developed coverage compared to high-income countries 10–12 .”
Mudenda, S., Hakayuwa, C. M., Lubanga, A. F., Kasanga, M., Daka, V., Salachi, K. I., Mwaba, M., Chileshe, C., Champo, M., Kamayani, M., et al. (2025) · Pharmacology & Pharmacy · doi:10.4236/pp.2025.167014 · Cited by 18
Yakobi, S. H., & Nwodo, U. U. (2025) · MicrobiologyOpen · doi:10.1002/mbo3.70037 · Cited by 17
Sarkodie-Addo, P., Aglomasa, B. C., & Donkor, E. S. (2025) · Tropical Medicine and Health · doi:10.1186/s41182-025-00731-7 · Cited by 16
Bwanali, A. N., Lubanga, A. F., Kondowe, S., Nzima, E., Mwale, A., Kamanga, W., Enerico, C., Masautso, C., Kapatsa, T., Mudenda, S., et al. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-11335-1 · Cited by 16
“Active surveillance of common infections, and antimicrobial susceptibility profiles provides a benchmark for antibiotic use and addressing resistance patterns in the fights against AMR [20].”
Mudenda, S., Kapolowe, K., Chirwa, U., Chanda, M., Chanda, R., Kalaba, R., Fwoloshi, S., Phiri, C. C., Mwamba, M., Chirwa, R. K., et al. (2025) · Antibiotics · doi:10.3390/antibiotics14030284 · Cited by 14
Aladejana, E. B., Adelabu, O. A., Aladejana, A. E., & Ndlovu, S. I. (2024) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2024.100432 · Cited by 14
Kasanga, M., Gajdács, M., Muleya, W., Ikhimiukor, O. O., Mudenda, S., Kasanga, M., Chizimu, J. Y., Shempela, D. M., Solochi, B. B., Mwikisa, M. J., et al. (2024) · Antibiotics · doi:10.3390/antibiotics13100951 · Cited by 12
“A 2019 study reported 3700 deaths directly attributable to AMR and 15,600 associated with AMR, ranking the country 191st globally [8,10,11].”
BackgroundGuido, G., Frallonardo, L., Asaduzzaman, M., Farkas, F. B., Vita, E. D., Seni, A., Cotugno, S., Papagni, R., Gomonda, E. D. S., Segala, F. V., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-01243-5 · Cited by 14
“In Africa Region, and particularly in SSA, reports of resistant pathogens are becoming increasingly prevalent 10 – 12 .”
Egwu, E., Ibiam, F. A., Moses, I. B., Iroha, C. S., Orji, I., Okafor-Alu, F. N., Eze, C. O., & Iroha, I. R. (2023) · Scientific African · doi:10.1016/j.sciaf.2023.e01863 · Cited by 20
Kawa, D. E., Tickler, I. A., Tenover, F. C., & Shettima, S. A. (2023) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed8110500 · Cited by 11
“Gram-negative bacteria, such as Escherichia coli , Klebsiella pneumoniae , Enterobacter spp., Pseudomonas aeruginosa, and Acinetobacter baumannii , are leading causes of antimicrobial-resistant infections [1] with resistance to fluoroquinolones and β -lactam drugs being widely reported [1,2].”
BackgroundVaghasiya, M. D., Mendapara, J. V., Ahmad, I., Patel, H., Rajani, D. P., & Kumari, P. (2024) · Journal of the Iranian Chemical Society · doi:10.1007/s13738-024-03011-z · Cited by 12
Mithi, B., Luhanga, M., Kaminyoghe, F., Chiumia, F. K., Banda, D. L., & Nyama, L. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-09333-w · Cited by 15
“These are among antibiotics with diminished effectiveness reported in many studies on antimicrobial resistance pattern in Malawi and sub-Saharan region [13, 14].”
BackgroundBennett, C., Russel, W. A., Upton, R. L., Frey, F. M., & Taye, B. (2024) · Antimicrobial Stewardship & Healthcare Epidemiology · doi:10.1017/ash.2024.375 · Cited by 12
Mthombeni, T. C., Burger, J. R., Lubbe, M. S., Julyan, M., & Lekalakala, R. (2024) · African Journal of Laboratory Medicine · doi:10.4102/ajlm.v13i1.2519 · Cited by 16
In-silico identification of potential inhibitors against FabI protein in Klebsiella pneumoniae
Khan, S., Madhi, S. A., & Olwagen, C. P. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2200571 · Cited by 11
“The emergence of multi-drug-resistant (MDR) KPN is a global health problem, especially in Sub-Saharan Africa where the burden of HIV infections are extremely high (Kariuki et al., 2022).”
BackgroundThe need to increase antimicrobial resistance surveillance among forcibly displaced persons (FDPs)
Yusuff, S. I., Tajudeen, Y. A., Oladunjoye, I. O., Oladipo, H. J., Bolarinwa, O. V., Popoola, O. T., Ahmed, A. F., & Olana, M. D. (2023) · Tropical Diseases Travel Medicine and Vaccines · doi:10.1186/s40794-023-00198-6 · Cited by 11
“…factors hindering the adequate implementation of NAPs, as elucidated by Kariuki et al., such as lack of political commitment, inadequate funding, and inadequate capacity [37], need to be swiftly addressed by conducting strategic advocacy to the policymakers to increase funding for AMR surveillance.”
BackgroundAppraising Nigeria’s approach to combating antimicrobial resistance
Onah, S. I., & Umar, H. J. (2023) · The International Journal of Health Planning and Management · doi:10.1002/hpm.3717 · Cited by 13
A Systematic Review of the Microbial Landscape of Diabetic Foot Ulcers in Uganda
Makeri, D., Eilu, E., Odoki, M., & Agwu, E. (2024) · Infection and Drug Resistance · doi:10.2147/idr.s446838 · Cited by 11
“40 In light of the growing concern over antimicrobial resistance and the limitations of current antibiotic therapies in Uganda, it is imperative to explore alternative treatment options for diabetic foot infections.”
BackgroundKıratlı, K., Aysın, M., Ali, M. A., Alı, A. M., Zeybek, H., & Köse, Ş. (2024) · Infection and Drug Resistance · doi:10.2147/idr.s463197 · Cited by 12
“1,13,14 In this ongoing, challenging battle against microbes, prescribers are the most significant target group, and their competencies and necessary knowledge have really been established.”
BackgroundA Review of Medicinal Plants Used in the Management of Microbial Infections in Angola
Tlhapi, D. B., Malebo, N. J., Manduna, I. T., Lautenschläger, T., & Mawunu, M. (2024) · Plants · doi:10.3390/plants13212991 · Cited by 16
Cong, W., Cheng, H., Stuart, B. L., Liu, B., Tang, Y., Wang, Y., Alhusein, N., Wang, H., Manchundiya, A., & Lambert, H. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad302 · Cited by 11
Rwigi, D., Nyerere, A. K., Diakhate, M. M., Kariuki, K. M., Tickell, K. D., Mutuma, T., Tornberg-Belanger, S. N., Soge, O. O., Walson, J. L., Singa, B. O., et al. (2024) · BMC Microbiology · doi:10.1186/s12866-024-03284-7 · Cited by 10
“Antimicrobial resistance (AMR) is a leading cause of death worldwide, with the highest burden reported in sub-Saharan Africa (SSA) where approximately 1.2 million deaths in 2019 were attributed to bacterial AMR [1, 2].”
InfluentialSelf-citationSono, T. M., Schellack, N., & Godman, B. (2024) · Advances in Human Biology · doi:10.4103/aihb.aihb_124_24 · Cited by 13
Gnimavo, M. S., Boya, B., Mudenda, S., & Allabi, A. C. (2024) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlae220 · Cited by 9
A systematic review and meta-analysis on antibiotic resistance genes in Ghana
Donkor, E. S., Odoom, A., Osman, A.-H., Darkwah, S. O., & Kotey, F. C. N. (2025) · BMC Medical Genomics · doi:10.1186/s12920-024-02050-y · Cited by 11
“In sub-Saharan Africa, overburdened health systems struggle to combat resistant infections, compounding crisis-level tuberculosis, HIV/AIDS, and malaria mortality [10, 11].”
Kumwenda, P., & Semu, P. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-10842-5 · Cited by 9
Prevalence of antimicrobial resistance in Somalia: A systematic review
Hassan, S. A., Osman, M. H., & Mohamed, M. A. (2025) · IJID Regions · doi:10.1016/j.ijregi.2025.100800 · Cited by 9
“Sub-Saharan Africa faces one of the world’s highest AMR-associated mortality rates, driven by a combination of a high burden of infectious diseases, weak health systems, poor sanitation, and the un-regulated availability of antimicrobial drugs [ 4 , 5 ].”
Singh, K., & Mitra, S. (2026) · Microorganisms · doi:10.3390/microorganisms14030527 · Cited by 9
“AMR in these regions is a symptom of deeper, interconnected challenges in development, governance, and health systems [10–12] The AMR surveillance in LMICs is primarily coordinated through global frameworks led by the World Organisation for Animal Health (WOAH) and the Food and Agriculture…”
InfluentialBouagnon, J. J. R., Konan, Y., Sinan, K. I., Konan, F., BOLOU, G. E.-K., Koffi, L. R., Dodéhé, Y., N’Guessan, J. D., Zengin, G., Djaman, A. J., et al. (2024) · Scientific African · doi:10.1016/j.sciaf.2024.e02058 · Cited by 10
Ong’era, E., Kagira, J. M., Maina, N. W., Kiboi, D. M., Waititu, K., Michira, L., & Ngotho, M. (2023) · BioMed Research International · doi:10.1155/2023/3573056 · Cited by 10
Byarugaba, I., Nabatanzi, A., Muhumuza, E., & Kyambadde, J. (2025) · BMC Microbiology · doi:10.1186/s12866-025-04024-1 · Cited by 9
“As a matter of concern, the World Health organization (WHO) has recognized antibiotic resistance as one of the top environmental health challenges facing humanity to date with the global mortality rate estimated at 700,000 deaths per year [21–23].”
Mike-Ogburia, M. I., Monsi, T. P., & Nwokah, E. G. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-11351-1 · Cited by 16
“Low-and middle-income countries, including those in sub-Saharan Africa, often face a disproportionate share of this burden [22, 23]; possibly due to factors such as limited healthcare infrastructure, inadequate surveillance systems, and over-the-counter access to antibiotics [24–26].”
Olaniyan, T. O., Martínez-Vázquez, A. V., Escobedo-Bonilla, C. M., López‐Rodríguez, C., Huerta-Luévano, P., Castrejón-Sánchez, O., de la Cruz-Flores, W. L., Castillo, M. J. C., de Luna-Santillana, E. D. J., Cruz-Hernández, M. A., et al. (2025) · Microbiology Research · doi:10.3390/microbiolres16090201 · Cited by 8
“The deaths caused by AMR in sub-Saharan Africa were estimated at 23.5 deaths per 100,000 people in 2019, the highest in the region [13].”
InfluentialWilson, C. N., Musicha, P., Beale, M. A., Diness, Y., Kanjerwa, O., Salifu, C., Katuah, Z., Duncan, P., Nyangu, J., Mungu, A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65266-1 · Cited by 9
“…occurred in sub-Saharan Africa, a consequence of prevailing levels of poverty leading to inadequate investment in sanitation and healthcare infrastructure, a high overall burden of infectious diseases, poor regulation of antimicrobial use and lack of alternatives to effective antimicrobials 13 .”
Ntshonga, P., Paganotti, G. M., & Gaibani, P. (2026) · Antibiotics · doi:10.3390/antibiotics15010069 · Cited by 11
Moloto, K., Newton-Foot, M., Whitelaw, A., & Dramowski, A. (2024) · PLoS ONE · doi:10.1371/journal.pone.0309315 · Cited by 8
“The highest AMR-attributable death rates observed in Sub-Saharan Africa were in 2019 at 27.3 deaths per 100 000 [5].”
BackgroundInfluentialLubanga, A. F., Bwanali, A. N., Kondowe, S., Nzima, E., Masi, A., Njikho, Y., Chitule, C., Harawa, G., Mudenda, S., Mwale, G., et al. (2025) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlaf103 · Cited by 9
Muturi, P., Mbae, C. K., Kibet, E., Njoroge, P., Kavai, S. M., Ideke, D. O., Jepchirchir, J., Gunn, J. S., & Kariuki, S. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1628784 · Cited by 8
Self-citationGetu, A., Solomon, T., Fikre, N., Eyasu, E., Fufa, Y., Tazebachew, M., & Alemu, Z. A. (2025) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/cjid/5354292 · Cited by 7
“High resistance rates are reported for pathogens like Escherichia coli and Klebsiella pneumoniae [7, 13, 14], with 57.6% of prescriptions inappropriately containing antibiotics [9].”
InfluentialÇelik, A. K., TÜRKAN, M., Ali, T. A., İsse, S. A., Mohmud, F. A., Hussein, L. A., & Alı, A. M. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-12315-1 · Cited by 7
“In Sub-Saharan Africa, AMR is estimated to contribute to 23.5 deaths per 100,000 population [14].”
InfluentialMuhammad, Z., Adamu, M. T., Garba, L., Tawfiq, U. A., & Yusuf, I. (2026) · Access Microbiology · doi:10.1099/acmi.0.001100.v3 · Cited by 7
“Sub-Saharan Africa faces a disproportionate burden from priority pathogens [13], yet environmental surveillance data specifically targeting WHO priority pathogens and ESKAPE organisms remain severely limited [14].”
Lotto, T. D., Renggli, S., Kaale, E. A., Masanja, H., Ternon, B., Decosterd, L. A., D’Acremont, V., Genton, B., & Kulinkina, A. V. (2024) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2024.05.004 · Cited by 7
Mayito, J., Tumwine, C., Galiwango, R. M., Nuwamanya, E., Nakasendwa, S., Mackline, H., Kiggundu, R., Byonanebye, D. M., Dhikusooka, F., Twemanye, V., et al. (2024) · JMIR Research Protocols · doi:10.2196/58116 · Cited by 9
Taxonomic and functional profiling of microbial community in municipal solid waste dumpsite
Mamo, Z., Abera, S., & Tafesse, M. (2024) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-024-04189-3 · Cited by 8
“Antimicrobial resistance (AMR) has become a critical global health crisis, with over 700,000 annual deaths caused by drug-resistant diseases (Kariuki et al. 2022 ), including 230,000 from multidrug-resistant tuberculosis (Dadgostar 2019 ).”
Opiyo, S. O., Nalunkuma, R., Nanyonga, S. M., Mugenyi, N., & Kanyike, A. M. (2025) · Wellcome Open Research · doi:10.12688/wellcomeopenres.21010.3 · Cited by 7
Ajao, A. A., & Moteetee, A. N. (2023) · Scientific African · doi:10.1016/j.sciaf.2023.e01934 · Cited by 7
Edet, U. O., Meseko, C. A., Okoroiwu, H. U., Elizabeth, M., Mkpuma, N., Cecilia, O.-K. I., & Fagbamila, I. O. (2025) · Scientific Reports · doi:10.1038/s41598-025-01398-0 · Cited by 7
“The widespread ofAMR genes in the region has been attributed to many factors, including the exit of pharmaceutical giants and the absence of AMR surveillance in the region 36,37 .”
Mohammed, Y., Muhammad, A. S., Zainu, S. M., Jimoh, A. K., Olowo‐okere, A., Ogunyinka, I. A., Abubakar, J., Dada, K. M., Egbe, O. E., & Galalain, S. M. (2024) · Annals of African Medicine · doi:10.4103/aam.aam_141_23 · Cited by 6
“[3] Generally, prevalence of A. baumannii vary according to geographic contexts, hospital units (intensive care unit [ICU] vs. other unit), patient’s body site (those with high fluid content‑cerebrospinal fluid, peritoneal fluid, respiratory and urinary tracts; contain more), disease severity…”
InfluentialAntibiotics Self-Medication Among Students at Faculty of Medical Technology, University of Tripoli
Elmahmoudi, H., & Atia, A. (2024) · Khalij-Libya Journal of Dental and Medical Research · doi:10.47705/kjdmr.248108 · Cited by 6
Kamara, I. F., Fofanah, B. D., Nuwagira, I. B., Kamara, K. N., Tengbe, S. M., Abiri, O. T., Kamara, R. Z., Lakoh, S., Farma, L., Kamara, A., et al. (2024) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-024-01425-1 · Cited by 10
“Antimicrobial resistance (AMR) is a global public health concern impacting individuals throughout their life course [1, 2].”
BackgroundMackline, H., Kiggundu, R., Byonanebye, D. M., Mayito, J., Tabajjwa, D., Lwigale, F., Tumwine, C., Mwanja, H., Kambugu, A., & Kakooza, F. (2024) · JMIR Research Protocols · doi:10.2196/58140 · Cited by 7
“In low-and middle-income countries, the capability for surveillance of AMR varies [9], with sub-Saharan Africa and Southeast Asia exhibiting the least developed coverage compared with high-income countries [10-12].”
Desye, B., Mawugatie, T. W., Asmare, L., Tsega, Y., Melak, D., Endawkie, A., & Daba, C. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1440908 · Cited by 11
Iram, Negi, A., Khan, A., Parveen, S., & Javed, M. S. (2024) · Waste and Biomass Valorization · doi:10.1007/s12649-024-02853-1 · Cited by 6
“The economic toll of AMR is also substantial, with estimates suggesting it could cost the world economy up to $100 trillion by 2050 [ 12 , 13 ].”
Mehari, M. G., Yeshiwas, A. G., Esubalew, D., Azmeraw, Y., Delie, A. M., Limenh, L. W., Worku, N. K., Hailu, M., Melese, M., Abie, A., et al. (2025) · Journal of Health Population and Nutrition · doi:10.1186/s41043-025-00767-9 · Cited by 7
“Policymakers should prioritize interventions aimed at improving diagnostic infrastructure and strengthening healthcare systems to address infections caused by P. aeruginosa in pregnancy, ultimately improving maternal and neonatal health outcomes in the region [33].”
Pious, N., Das, S., Chakravorty, A., Mini, A. A., & Raghavan, V. (2025) · RSC Advances · doi:10.1039/d5ra04732c · Cited by 7
“37,38 By presenting these comparative PK/PD data in tabular or narrative form, a clearer understanding can be provided of those clinical scenarios in which gati oxacin, based on its pharmacological characteristics, may be preferred, as well as those in which alternative uoroquinolones may…”
Gashegu, M., Ndahindwa, V., Rwagasore, E., Tuyishime, A., Musanabaganwa, C., Gahamanyi, N., Mukagatare, I., Mbarushimana, D., Green, C., Dzinamarira, T., et al. (2024) · Antibiotics · doi:10.3390/antibiotics13111084 · Cited by 8
Adjei, S. K., & Adjei, P. (2025) · Health Science Reports · doi:10.1002/hsr2.71029 · Cited by 9
“AMR is projected to result in approximately 700,000 fatalities annually worldwide [15].”
Quansah, K. E., Ahmed, H., Thekkur, P., Hedidor, G. K., Adomako, L. A. B., Banu, R. A., Akrong, M. O., Borbor, S., Buri, N. M., Bello, M., et al. (2025) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed10100291 · Cited by 9
“Surveillance of drinking water is therefore key to tracking AMR trends and guiding targeted, evidence-based interventions [24–26].”
Xavier, S. P. (2025) · Discover Public Health · doi:10.1186/s12982-025-01083-7 · Cited by 7
“This commentary aims to highlight the challenges of AMR in SSA, where the problem is exacerbated by factors such as high poverty rates, a heavy burden of infectious diseases, inadequate regulation of antimicrobial use, and a lack of effective therapeutic alternatives [7].”
Trends in morbidity and mortality from bacterial infections in hospitals in Northwest Ethiopia
Abejew, A. A., Wubetu, G. Y., & Fenta, T. G. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-12054-3 · Cited by 7
“Bacterial infections, including healthcare-associated infections (HAIs), are prevalent and major causes of death in Ethiopia [8, 14, 18–23].”
Raut, N., Chaudhary, A. A., Patil, H., Shidhaye, S., Khobragade, R., Umekar, M. J., Ali, M. A. M., & Trivedi, R. (2026) · Pathogens · doi:10.3390/pathogens15040414 · Cited by 8
“The Sub-Saharan Africa (SSA) region is disproportionately affected by AMR, in part owing to the prevailing high levels of poverty, which strain health systems, lead to poor regulation of antimicrobial use, and leave few options for ineffective antimicrobials [24].”
Abejew, A. A., Fenta, T. G., & Wubetu, G. Y. (2025) · BioMed Research International · doi:10.1155/bmri/7676973 · Cited by 6
Metadata
- Authors
- Kariuki, S., Kering, K., Wairimu, C., Onsare, R., & Mbae, C.
- Affiliations
- Kenya Medical Research Institute (KE)
- Corresponding author
- Kariuki, Samuel
- Kering, Kelvin
- Wairimu, Celestine
- Mbae, Cecilia
- Venue
- Infection and Drug Resistance
- Publisher
- Informa UK Limited
- Published
- 2022-07
- Volume
- Volume 15
- Pages
- 3589-3609
- ISSN
- 1178-6973 (ISSN-L)
- PMC
- PMC9273632
- OpenAlex
- W4284678172
- Cited by
- 245
- References
- 189
- Citations by year
- 2026: 72 · 2025: 92 · 2024: 53 · 2023: 27 · 2022: 1
- FWCI
- 5.80
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Infection and Drug Resistance (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc-sa)
- Funders
- Wellcome Trust (215675/Z/19/Z)
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases (R01AI099525)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Life Sciences › Agricultural and Biological Sciences › Food Science › Salmonella and Campylobacter epidemiology
- Keywords
- antimicrobial resistance, antimicrobial resistance surveillance, sub-Saharan Africa, national action plans, One Health, antimicrobial stewardship, infection control, water, sanitation and hygiene, antimicrobial use regulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.